Objective  To explore the risk factors of peripheral intravenous infusion phlebitis (IP) in cervical carcinoma (CC) patients, and construct a risk prediction model of peripheral venous IP.

Methods  Information of CC patients in the obstetrics and gynecology department of the First People's Hospital of Suqian city from January 2019 to May 2024 was retrospectively collected. CC patients from January 2019 to December 2023 were included in the training set, and CC patients from January 2024 to May 2024 were included in the internal validation set. Patients were divided into IP and non IP groups based on whether IP had occurred. Single factor analysis and stepwise Logistic regression were used to screen the influencing factors of peripheral venous IP in CC patients, and prediction model was constructed. The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC), calibration curve, and decision curve were used to evaluate the predictive performance, accuracy, and clinical adaptability of the risk prediction model.

Results  A total of 349 CC patients were included, and the incidence of peripheral venous IP was about 14.33%. In the training set, there were 289 CC patients, and peripheral venous IP occurred in 41 cases. In the validation set, there were 60 CC patients, and peripheral venous IP occurred in 9 cases. Stepwise multivariate Logistic regression analysis showed that the combination of diabetes, right puncture, lower limb puncture, and total amount of infusion ≥ 2 000 mL were risk factors for the peripheral vein IP in CC patients, while infusion heating was a protective factor for the peripheral vein IP in CC patients. Probability of peripheral venous IP =1/[1+e^(-(1.231×Diabetes+1.075×Puncture site+2.935×Puncture limb +0.856×Infusion volume-0.983×Infusion heating))]. ROC analysis showed that the AUC (95%CI) of the risk prediction model for peripheral venous IP in the training set and internal validation set was 0.807 (0.738, 0876) and 0.838 (0.719, 0.956), respectively. The calibration curve indicated that the predicted probability and actual occurrence probability were roughly consistent, and the decision curve indicates that within a certain threshold range, it could benefit clinical practice. The results of calibration curve and clinical decision curve in the internal validation set were not good.

Conclusion  The risk prediction model of peripheral venous IP constructed in this study has certain predictive ability and clinical applicability, which can help nursing staff identify peripheral venous IP in CC patients in the early stage. Further validation is still needed through large-scale research in the future.

1.唐江月, 王琳, 张婧, 等. 信迪利单抗联合调强适形放疗和化疗对晚期宫颈癌患者的临床疗效和安全性评价[J]. 中国药师, 2023, 26(12): 456-464. [Tang JY, Wang L, Zhang J, et al. Efficacy and safety of sindilizumab combined with intensity modulated radiotherapy and chemotherapy in patients with advanced cervical cancer[J]. China Pharmacist, 2023, 26(12): 456-464.] DOI: 10.12173/j.issn.1008-049X.202311277.

2.舒敏, 韩志红, 韩妍, 等. 血府逐瘀汤对晚期宫颈癌化疗患者的疗效和安全性研究[J]. 中国药师, 2023, 26(12): 428-434. [Shu M, Han ZH, Han Y, et al. Efficacy and safety of Xuefu Zhuyu decoction in patients with advanced cervical cancer[J]. China Pharmacist, 2023, 26(12): 428-434.] DOI: 10.12173/j.issn.1008-049X.202310031.

3.赵琛, 宋淑芳. 我国宫颈癌流行病学及病因学的研究 [J]. 医学信息, 2021, 34(5): 6-8. [Zhao C, Song SF. The epidemiology and etiology of cervical cancer in China[J]. Medical Information, 2021, 34(5): 6-8.] DOI: 10.3969/j. issn.1006-1959.2021.05.002.

4.Marsh N, Webster J, Ullman AJ, et al. Peripheral intravenous catheter non-infectious complications in adults: a systematic review and Meta-analysis[J]. J Adv Nurs, 2020, 76(12): 3346-3362. DOI: 10.1111/jan.14565.

5.Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters[J]. Cochrane Database Syst Rev, 2019, 1(1): CD007798. DOI: 10.1002/14651858.CD007798.pub5.

6.白萍,魏永婷,孙智超,等.肿瘤手术病人外周静脉输液性静脉炎发生风险预测模型的构建[J].护理研究, 2023, 37(11): 1914-1920. [Bai P, Wei YT, Sun ZC, et al. Construction of the risk prediction model for infusion phlebitis of peripheral vein in patients undergoing tumor surgery [J]. Chinese Nursing Research, 2023, 37(11):1914-1920. DOI:10.12102/j.issn.1009-6493.2023.11.006.

7.杜娟,马云,赵育刚,等.何氏解毒消炎散外敷治疗输液性静脉炎的临床疗效观察[J].成都医学院学报, 2020, 15(4): 464-467. [Du J, Ma Y, Zhao YG, et al. The observation of clinical effect of Ho's Jiedu Xiaoyan Powder applied externally in the treatment of infusion phlebitis[J]. Journal of Chengdu Medical College, 2020, 15(4):464-467.] DOI: 10.3969/j.issn.1674-2257.2020.04.012.

8.Saini V, Samra T, Ahuja N, et al. A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1 000 IU/mL) compared to heparin topical gel (200  IU/g) in prevention of infusion-associated phlebitis[J].Indian J Pharmacol, 2018, 50(6): 344-349. DOI: 10.4103/ijp.IJP_201_17.

9.Gorski LA. A look at 2021 infusion therapy standards of practice[J]. Home Healthc Now, 2021, 39(2): 62-71. DOI: 10.1097/NHH.0000000000000972.

10.刘秋秋, 张小琼, 李希. 术中穿刺部位静脉炎发生原因分析及对策[J]. 护理学杂志, 2005, (2): 51-52. [Liu QQ, Zhang XQ, Li X. Causal analysis of phlebitis at puncture site in patients undergoing venous general anesthesia[J]. Journal of Nursing Science, 2005, (2): 51-52.] DOI: 10.3969/j.issn.1001-4152.2005.02.026.

11.陈亚美. 外周静脉导管相关静脉炎风险评估模型的构建[D]. 苏州: 苏州大学, 2020. [Chen YM. Construction of a risk assessment model for peripheral venous catheter-related phlebitis[D]. Suzhou: Suzhou University, 2020.] DOI: 10.27351/d.cnki.gszhu.2019.002340.

12.王磊, 张超, 任爱霞, 等. 中药塌渍治疗糖尿病病人输液性静脉炎的效果[J]. 齐鲁医学杂志, 2014, 29(3): 261-262. [Wang L, Zhang C, Ren AX, et al. Effect of traditional Chinese medicine on infusion phlebitis in patients with diabetes[J]. Medical Journal of Qilu, 2014, 29(3): 261-262.] DOI: 10.13362/j.qlyx.201403029.

13.张宇涵, 马岩, 彭宇, 等. 自体动静脉内瘘血栓危险因素的Meta分析[J]. 中国血液净化, 2021, 20(2): 126-129. [Zhang YH, Ma Y, Peng Y, et al. Systematic review and Meta analysis of the risk factors for thrombosis in arteriovenous fistula[J]. Chinese Journal of Blood Purification, 2021, 20(2): 126-129.] DOI: 10.3969/j.issn.1671-4091.2021.02.013.

14.Guanche-Sicilia A, Sánchez-Gómez MB, Castro-Peraza ME, et al. Prevention and treatment of phlebitis secondary to the insertion of a peripheral venous catheter: a scoping review from a nursing perspective[J]. Healthcare (Basel), 2021, 9(5): 611. DOI: 10.3390/healthcare9050611.

15.陶艳玲, 周春兰. 静脉留置针相关静脉炎的危险因素研究进展[J]. 护理学杂志, 2014, 29(20): 89-92. [Tao YL, Zhou CL. Research progress on risk factors of venous catheterization associated phlebitis[J]. Journal of Nursing Science, 2014, 29(20): 89-92.] DOI: 10.3870/hlxzz.2014.20.089.

16.Lee S, Kim K, Kim JS. A model of phlebitis associated with peripheral intravenous catheters in orthopedic inpatients[J]. Int J Environ Res Public Health, 2019, 16(18): 3412. DOI: 10.3390/ijerph16183412.

17.马平平, 张美丽. 静脉输液患儿发生静脉炎的现状调查及危险因素分析[J]. 中国妇幼保健, 2023, 38(16): 3086-3089. [Ma PP, Zhang ML. A survey on the current situation and risk factors of phlebitis in children undergoing intravenous infusion[J]. Maternal & Child Health Care of China, 2023, 38(16): 3086-3089.] DOI: 10.19829/j. zgfybj. issn.1001-4411.2023.16.037.

18.Dillon RC, Merchan C, Altshuler D, et al. Incidence of adverse events during peripheral administration of sodium chloride 3[J]. J Intensive Care Med, 2018, 33(1): 48-53. DOI: 10.1177/0885066617702590.